LaShell Robinson

home / authors / lashell-robinson

LaShell Robinson is the executive director and global head for global feasibility and trial equity at Takeda Pharmaceuticals.

Articles

LaShell Robinson on Takeda’s Initiative to Improve Research Diversity

LaShell Robinson on Takeda’s Initiative to Improve Research Diversity

Maddi Hebebrand, MC, Associate Editor;LaShell Robinson
March 5th 2025

Robinson shared insights into how the company is working to fight clinical research disparities.

Latest Updated Articles

2 KOLs are featured in this series.
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Published: March 11th 2025 | Updated: March 31st 2025
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Apoptosis-Based Skin Cancer Treatment Shows Promise
Published: March 15th 2025 | Updated: March 31st 2025
Apoptosis-Based Skin Cancer Treatment Shows Promise
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
Published: March 7th 2025 | Updated: March 31st 2025
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
Published: March 8th 2025 | Updated: March 31st 2025
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
Published: March 8th 2025 | Updated: March 31st 2025
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
© 2025 MJH Life Sciences

All rights reserved.